Cytokinetics Inc CYTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Cytokinetics to Participate in November Investor Conferences
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Trading Information
- Previous Close Price
- $53.17
- Day Range
- $51.37–52.98
- 52-Week Range
- $51.37–88.31
- Bid/Ask
- $50.00 / $54.42
- Shares Outstanding
- 139.30M
- Market Cap
- $7.20B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 64.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 673
- Website
- https://www.cytokinetics.com
Competitors
Valuation
Metric | CYTK | SNY | BMY |
|---|---|---|---|
Price/Earnings (Normalized) | — | 12.54 | 10.18 |
Price/Book Value | — | 1.40 | 5.54 |
Price/Sales | 64.04 | 1.97 | 2.60 |
Price/Cash Flow | — | 8.41 | 8.35 |
Price/Earnings
CYTK
SNY
BMY
Financial Strength
Metric | CYTK | SNY | BMY |
|---|---|---|---|
Quick Ratio | 3.29 | 0.21 | 1.36 |
Current Ratio | 3.36 | 1.12 | 1.59 |
Interest Coverage | −5.06 | 9.10 | 7.86 |
Quick Ratio
CYTK
SNY
BMY
Profitability
Metric | CYTK | SNY | BMY |
|---|---|---|---|
Return on Assets (Normalized) | −41.06% | 8.44% | 14.17% |
Return on Equity (Normalized) | — | 15.62% | 62.00% |
Return on Invested Capital (Normalized) | −73.84% | 12.02% | 20.89% |
Return on Assets
CYTK
SNY
BMY
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|dD%w<M | LOCK|jFhS | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Zk>#%d? | LOCK|#M$F | $99B | |||
| Moderna Inc MRNA | LOCK|#lgSQK | LOCK|TB | $87B | |||
| argenx SE ADR ARGX | LOCK|y>#JbV | LOCK|bL | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|zX?XbMV | LOCK|Mc! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^$jpR%@ | LOCK|DdlR | $31B | |||
| Incyte Corp INCY | LOCK|HhMVv! | LOCK|n!z | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|sZV^r!m | LOCK|c#qJ | $21B | |||
| BioNTech SE ADR BNTX | LOCK|np%FpM | LOCK|Xm | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&hkq??# | LOCK|<qr | $15B |